As the first step in AD development, a decrease in CBF occurs before the appearance of clinical symptoms, which suggests its potential inducing role of AD pathological changes, including the expression of amyloid precursor protein (APP) and tau phosphorylation (Koike et al., 2010; Wang et al., 2010; Salminen et al., 2017). This evidence concerns the gene APP and Alzheimer disease.